Interferences of the autonomic nervous system with drug induced QT prolongation: A point to consider in non-clinical safety studies

Journal of Pharmacological and Toxicological Methods

Volumn 61, Issue 3, 2010, Pages 251-263

  Champeroux, Pascal ^a   Ouillé, Aude ^b   Martel, Eric ^a   Fowler, John Sinclair Lawrence ^a   Maurin, Anne ^a   Jude, Sébastien ^a   Lala, Patricia ^a   Le Guennec, Jean Yves ^b   Richard, Serge ^a  

^a CERB   (France)

^b UNIVERSITÉ DE TOURS   (France)

Author keywords

Beagle dogs; Electrocardiogram; Probabilistic method; QT prolongation; Safety pharmacology; Terfenadine; Thioridazine

Indexed keywords

ATENOLOL; CLONIDINE; TERFENADINE; THIORIDAZINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTONOMIC NERVOUS SYSTEM; BRADYCARDIA; CONTROLLED STUDY; DOG; DRUG SAFETY; ELECTROCARDIOGRAM; FEMALE; HEART RATE; MALE; NONHUMAN; PARASYMPATHETIC TONE; QT INTERVAL; QT PROLONGATION; RR INTERVAL; SYMPATHETIC TONE; TACHYCARDIA; TELEMETRY;

ANIMALIA; CANIS FAMILIARIS;

EID: 77952289506     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vascn.2010.02.006     Document Type: Article

References (40)

1. Batey A.J., Doe C.P. A method for QT correction based on beat-to-beat analysis of the QT/RR interval relationship in conscious telemetred beagle dogs. Journal of Pharmacological Toxicological Methods 2002, 48:11-19.
2. Bazett J. An analysis of time relation of electrocardiograms. Heart 1920, 7:353-367.
3. Boucher M., Dubar M., Chapuy E., Chassaing C. Interactions of the cardiac chronotropic effects of rilmenidine with the autonomic nervous system. Journal of Autonomic Pharmacology 1996, 16:13-20.
4. Champeroux P., Martel E., Fowler J.S., Maurin A., Sola M.L., Jude S., et al. Calculation of QT shift in non clinical safety pharmacology studies. Journal of Pharmacological Toxicological Methods 2009, 59:73-85.
5. Champeroux P., Viaud K., El Amrani A.I., Fowler J.S., Martel E., Le Guennec J.Y., et al. Prediction of the risk of Torsade de Pointes using the model of isolated canine Purkinje fibres. British Journal of Pharmacology 2005, 144:376-385.
6. De Ponti F., Cavalli A., Recanatini M., Montanaro N. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce Torsade de pointes: An overview. Drug Safety 2002, 25:263-286.
7. Ekins S., Crumb W.J., Sarazan R.D., Wikel J.H., Wrighton S.A. Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-gogo-related gene potassium channel. Journal of Pharmacological and Experimental Therapeutics 2002, 301:427-434.
8. Fossa A.A. The impact of varying autonomic states on the dynamic beat-to-beat QT-RR and QT-TQ interval relationships. British Journal of Pharmacology 2008, 154:1508-1515.
9. Fossa A.A., Wisialowski T., Magnano A., Wolfgang E., Winslow R., Gorczyca W., et al. Dynamic beat-to-beat modelling of the QT-RR interval relationship: Analysis of QT prolongation during alterations of autonomic state versus human ether a-go-go-related gene inhibition. Journal of Pharmacological and Experimental Therapeutics 2004, 312:1-11.
10. Fridericia L. Die systolendauer in electrocardiogram bei normalen menchen und bei herzkranken. Acta Medica Scandinavia 1920, 53:469-486.
11. Gauvin D.V., Tilley L.P., Smith F.W., Baird T.J. Electrocardiogram, hemodynamics, and core body temperatures of the normal freely moving laboratory beagle dog by remote radiotelemetry. Journal of Pharmacological Toxicological Methods 2006, 53:128-139.
12. Gauvin D.V., Tilley L.P., Smith F.W., Baird T.J. Electrocardiogram, hemodynamics, and core body temperatures of the normal freely moving cynomolgus monkey by remote radiotelemetry. Journal of Pharmacological Toxicological Methods 2006, 53:140-151.
13. Gralinski M.R. The dog's role in the preclinical assessment of QT interval prolongation. Toxicologic Pathology 2003, 31:11-16.
14. Guth B.D., Bass A.S., Briscoe R., Chivers S., Markert M., Siegl P.K.S., et al. Comparison of electrocardiographic analysis for risk of QT interval prolongation using safety and toxicological studies. Journal of Pharmacological Toxicological Methods 2009, 60:107-116.
15. Hanson L.A., Bass A.S., Gintant G., Mittelstadt S., Rampe D., Thomas K. ILSI-HESI cardiovascular safety subcommittee initiative: Evaluation of three non-clinical models of QT prolongation. Journal of Pharmacological Toxicological Methods 2006, 54:116-129.
16. Harada T., Abe J., Shiotani M., Hamada Y., Horii I. Effect of autonomic nervous function on QT interval in dogs. The Journal of Toxicologic Scienses 2005, 30:229-237.
17. Holbrook M., Malik M., Shah R.R., Valentin J.P. Drug induced shortening of the QT/QTc interval: An emerging safety issue warranting further modelling and evaluation in drug research and development?. Journal of Pharmacological Toxicological Methods 2009, 59:21-28.
18. Holzgrefe H.H., Cavero I., Buchanan L.V., Gill M.W., Durham S.K. Application of a probabilistic method for the determination of drug-induced QT prolongation in telemetered cynomolgus monkeys: Effects of moxifloxacin. Journal of Pharmacological Toxicological Methods 2007, 55:244-254.
19. Holzgrefe H.H., Cavero I., Gleason C.R. Analysis of the nonclinical telemetered ECG: Impact of logging rate and RR bin width in the dog and cynomolgus monkey. Journal of Pharmacological Toxicological Methods 2007, 56:34-42.
20. Holzgrefe H.H., Cavero I., Gleason C.R., Warner W.A., Buchanan L.V., Gill M.W., et al. Novel probabilistic method for precisely correcting the QT interval for heart rate in telemetered dogs and cynomolgus monkeys. Journal of Pharmacological Toxicological Methods 2007, 55:159-175.
21. Hondeghem L.M., Snyders D.J. Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. Circulation 1990, 81:686-690.
22. + current by dofetilide. Circulation Research 1993, 72:75-83.
23. Katchman A.N., Koerner J., Tosaka T., Woosley R.L., Ebert S.N. Comparative evaluation of hERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs. Journal of Pharmacological and Experimental Therapeutics 2006, 316:1098-1106.
24. King A., Bailie M., Olivier N.B. Magnitude of error introduced by application of heart rate correction formulas to the canine QT interval. Annals of Noninvasive Electrocardiology 2006, 11(4):289-298.
25. Lindgren S., Bass A.S., Briscoe R., Bruse K., Friedrichs G.S., Kallman M.J., et al. Benchmarking safety pharmacology regulatory packages and best practices. Journal of Pharmacological Toxicological Methods 2008, 58:99-109.
26. Lu H.R., Vlamincks E., Hermans A.N., Rohrbacher J., Van Ammel K., Towart R., et al. Predicting drug-induced changes in QT interval and arrhythmias: QT shortening drugs point to gaps in the ICHS7B guidelines. British Journal of Pharmacology 2008, 154:1427-1438.
27. Matsunaga T., Mitsui T., Harada T., Inokuma M., Murano H., Shibutani Y. QT corrected for heart rate and relation between QT and RR intervals in beagle dogs. Journal of Pharmacological Toxicological Methods 1998, 38:201-209.
28. Miyazaki H., Tagawa M. Rate-correction technique for QT interval in long-term telemetry ECG recording in beagle dogs. Experimental Animals 2002, 51:465-475.
29. Napier L.D., Stanfill A., Yoshishige D.A., Jackson K.E., Borron B.A., Caffrey J.L. Autonomic control of heart rate in dogs treated chronically with morphine. American Journal of Physiology 1998, 44:2199-2210.
30. Nolan E.R., Bailie M.B., Olivier N.B. Effect of autonomic blockade on ventricular repolarization shortening: Response to behavioral stimulus in paced dogs. Autonomic Neurosciense: Basic & Clinical 2008, 140:66-71.
31. Ollerstam A., Persson A.H., Visser S.A.G., Fredericksson J.M., Forsberg T., Nilsson L.B., et al. A novel approach to data processing of the QT interval response in the conscious telemetered beagle dog. Journal of Pharmacological Toxicological Methods 2007, 55:35-48.
32. Redfern W.S., Carlsson L., Davis A.S., Lynch W.G., MacKenzie I., Palethorpe S., et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and Torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovascular Research 2003, 58:32-45.
33. Sides G.D. QT interval prolongation as a biomarker for torsades de pointes and sudden death in drug development. Disease Markers 2002, 18:57-62.
34. Spence S., Soper K., Hoe C.M., Coleman J. The heart rate-corrected QT interval of conscious beagle dogs: A formula based on analysis of covariance. Toxicological Scienses 1998, 45:247-258.
35. Towart R., Linders J.T., Hermans A.N., Rochbacher J., Van der Linde H.J., Ercken M., et al. Blockade of the I(Ks) potassium channel: An overlooked cardiovascular liability in drug safety screening?. Journal of Pharmacological Toxicological Methods 2009, 60:1-10.
36. Toyoshima S., Kanno A., Kitayama T., Sekiya K., Nakai K., Haruna M., et al. QT PRODACT: In vivo QT assay in the conscious dog for assessing the potential for QT interval prolongation by human pharmaceuticals. Journal of Pharmacological Scienses 2005, 99:459-471.
37. Van de Water A., Verheyen J., Xhonneux R., Reneman R.S. An improved method to correct the QT interval of the electrocardiogram for changes in heart rate. Journal of Pharmacological Toxicological Methods 1989, 22:207-217.
38. Van der Linde H.J., Van Deuren B., Teisman A., Towart R., Gallagher D.J. The effect of changes in core body temperature on the QT interval in beagle dogs: A previously ignored phenomenon, with a method for correction. British Journal of Pharmacology 2008, 154:1474-1481.
39. Vargas H.M., Bass A.S., Breidenbach A., Feldman H.S., Gintant G.A., Harmer A.R., et al. Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics. Journal of Pharmacological Toxicological Methods 2008, 58:72-76.
40. Ks to canine ventricular repolarization: Key role for beta-adrenergic receptor stimulation. Circulation 2003, 107:2753-2760.